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Community-acquired pneumonia (CAP) is a curable disease. Both the European and American
clinical practice guidelines provide algorithms how to manage patients with CAP.
However, as populations worldwide are ageing and bacteria are becoming multidrug resis-
tant, it is necessary to address the major factors that put patients at risk of poor outcome.
These may include age, comorbidities, the settings where pneumonia was acquired or treated,
the need for hospitalisation or ICU admission, likely causative pathogen (bacteria or virus) in a
certain region and their local susceptibility pattern. One complicating fact is the lack of def-
inite causative pathogen in approximately 50% of patients making it difficult to choose the
most appropriate antibiotic treatment. When risk factors are present simultaneously in pa-
tients, fewer treatment options could be rather challenging for physicians. For example, the
presence of comorbidities (renal, cardiac, hepatic) may exclude certain antibiotics due to po-
tential adverse events.
Assessing the severity of the disease and monitoring biomarkers, however, could help phy-
sicians to estimate patient prognosis once diagnosis is confirmed and treatment has been initi-
ated. This review article addresses the most important risk factors of poor outcome in CAP
patients.
ª 2014 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-
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Community-acquired pneumonia (CAP) is one of the most
common infectious diseases and a major cause of morbidity
and mortality worldwide [1], and is the most common in-
fectious cause of death in the developed world [2,3] with
rates as high as 48% [2,4,5]. Although CAP can occur at any
age, in the past few decades, the epidemiology of CAP has
undergone a marked shift and patients are now presenting
at an increasingly older age [6]. For this reason, the
occurrence of CAP in developed countries is likely to in-
crease in the coming years due to the ageing populations
[2,7].
While 50e80% of adult CAP patients are treated on an
ambulatory basis, hospitalisations are common, particularly
among the elderly [8e10] with admissions being highest
among patients over the age of 65 years [2,10,11]. The high
rate of hospital admission, prolonged stay in hospital and
long periods of inactivity associated with CAP lead to
considerable socioeconomic burden [2,3]. In addition,
comorbidities are common in CAP patients and increase the
risk of mortality and hospitalisation [12].
However, hospitalisation rates have fallen in recent
years following recent developments in the use of bio-
markers and prognostic tools to predict disease severitye 1 Prevalence of pathogens isolated in community-
ired pneumonia by treatment setting.
Outpatients
(%)
Hospitalised
patients
non-ICU (%)
ICU
patients
(%)
neumoniae 38 27 28
neumoniae 8 5 2
fluenzae 13 6 7
neumoniae 21 11 4
ureus 1.5 3 9
robacteriaceae 0 4 9
ruginosa 1 3 4
onella spp. 0 5 12
urnetii 1 4 7
iratory viruses 17 12 3
nown 50 41 45
intensive care unit.
oduced with permission from Welte et al. Thorax 2012 [5].[12e16], advances in antibiotic therapy [17e19] and in-
clusion of criteria for hospitalisation in current guidelines
for the management of CAP patients [20].
Identification of patients at risk of poor outcomes from
CAP is important since it affects both treatment and clinical
outcome. Outcome is also affected by inappropriate choice
of empiric treatment, since it has been found to be an in-
dependent risk factor for early treatment failure or death
[21,22]. This paper will review the factors influencing the
degree of risk for poor outcome in patients with CAP and
look at strategies designed to optimise therapeutic man-
agement of the condition.
The ‘at risk’ patient
A number of variables are associated with increased risk of
poor outcome, including the aetiology [6] and severity of
the disease [23], the age of the patient [12], presence of
comorbid illnesses [24], and the setting [6] in which pa-
tients are treated.
Aetiology
Although identifying the causative pathogen in CAP can
help guide selection of the most appropriate antibiotic
therapy, a microbiological diagnosis cannot be made in
around 50% of patients [25], possibly due in part to diffi-
culties associated with collecting valid sputum samples in
elderly patients [26]. Nevertheless, a wide range of path-
ogens have been found to cause CAP, with the most com-
mon being Streptococcus pneumoniae, Chlamydophila
pneumoniae, Haemophilus influenzae, Legionella spp.,
Staphylococcus aureus and Enterobacteriaceae [5]; similar
bacteriological patterns occur in younger and older patients
[26]. Of these pathogens, S. pneumoniae is the most
frequently isolated, both in outpatients and hospitalised
patients, including those in the intensive care unit (ICU)
[5,27] (Table 1). S. pneumoniae is also reported to be
common in patients with severe sepsis [28] and has been
found to trigger bacteraemia and sepsis in mouse lung
infection models [29]. H. influenzae is the second most
frequently isolated pathogen, being found in 5e14% of
elderly CAP patients [5,26,30]. Although S. aureus is a
relatively uncommon cause of CAP, outcomes for patients
with S. aureus CAP are poor [31]. Furthermore, methicillin-
resistant S. aureus (MRSA) is becoming an increasingly
Table 2 Clinical assessment of severity using the CRB-65, CURB-65 [60] and PSI [61] indices.
CRB-65 CURB-65 PSI
 Confusion  Confusion Criteria included (score)
 Respiratory rate
30/min
 Respiratory rate
30/min
 Age (years)a  Pleural effusion (þ10 points)
 Blood pressure (SBP
<90 mmHg or DBP
<60 mmHg)
 Urea (>7 mmol/L)  Nursing home residency
(þ10 points)
 Oxygenation parameters
(10e30 points/criteria)d
 Age >65 yrs  Blood pressure (SBP
<90 mmHg or DBP
<60 mmHg)
 Comorbidity (10e30
points/illness)b
 Laboratory abnormalities
(10e20 points/abnormality)e
 Age >65 yrs  Vital sign abnormalities
(10e20 points/abnormality)c
Points Risk category Score Predicted mortality rate (%)
0 Mortality: low (1.2%)
Treatment options:
suitable for treatment
outside the hospital
I e 0.1
1 or 2 Mortality:
intermediate (8.15%)
Treatment options:
consider hospital
referral and
assessment
II 70 points 0.6
‡3 Mortality: high (31%)
Treatment options:
urgent hospital
admission
III 71e90 points 0.9
IV 91e130 9.3
V >130 points 27.0
CRB-65, Confusion, Respiratory rate, low Blood pressure, age >65 years; CURB-65, Confusion, Uraemia, Respiratory rate, low Blood
pressure, age >65 years; DBP, diastolic blood pressure; PSI, Pneumonia Severity Index; SBP, systolic blood pressure.
a Number of years converts to points (10 points for women).
b Neoplastic disease (30 points), liver disease (20 points), congestive heart failure (10 points), cerebrovascular disease (10 points),
renal disease (10 points).
c Disorientation (20 points), respiratory rate 30/min (20 points), systolic blood pressure <90 mmHg (20 points), temperature <35 C
or 40 C (15 points), pulse 125/min (10 points).
d Partial pressure of arterial oxygen <60 mmHg (10 points).
e Haematocrit <30% (10 points), arterial pH < 7.35 (30 points), blood urea nitrogen 30 ng/dL (20 points), sodium <130 mmol/L (20
points), glucose 250 mg/dL (10 points).
Managing high-risk CAP patients 159common cause of S. aureus infections and its detection is
associated with a more severe clinical presentation of CAP
[27,32]. Common features associated with MRSA isolation
include patient history of MRSA, nursing home admission in
the previous year, close contact with someone with a skin
infection, multiple infiltrates or cavities on chest X-ray and
comatose state, intubation, receipt of pressors or death in
the emergency department [32]. Additional risk factors for
CAP due to MRSA include previous MRSA infection or expo-
sure to antibiotics [33,34], diabetes [33], illicit drug abuse
[35,36] and presence of indwelling catheters [34,37].
Legionella spp. (predominantly L. pneumophila) are
frequent causative atypical pathogens in CAP and occur
equally in outpatients and hospitalised patients (w4% of
cases in each), though frequencies reported in the litera-
ture vary considerably (0e25%), most likely due to differ-
ences in the patient populations studied andmicrobiological techniques used for detection [5,38,39].
Legionella pneumonia differs significantly in ambulatory
and hospitalised patients in both clinical characteristics
and outcome, with ambulatory patients tending to be
younger, with less comorbidity resulting in a milder course
without fatalities [38]. Legionella CAP is also associated
with high rates of discordant initial antibiotic treatment,
particularly in hospitalised patients, underlying the need
for urinary antigen testing to exclude Legionella before
discontinuation of atypical coverage [38,40].
Mycoplasma pneumoniae or C. pneumoniae are impor-
tant atypical pathogens causing CAP in regions such as
China [41e43], or Japan [41,44], and occasionally these
may lead to outbreaks in every 3e5 years in Europe and US
[45]. Macrolide resistance of M. pneumoniae is of particular
concern in areas with high prevalence such as China
[46,47]. Since beta-lactam antibiotics are not suitable
160 T. Welteagents against atypical pathogens, broad-spectrum fluo-
roquinolones may be chosen when the presence of atypical
is confirmed. Pneumonia caused by M. pneumoniae and C.
pneumoniae in most cases is of mild-to-moderate severity;
a severe course of the disease is seldom and mortality is low
[48,49]. Even with inadequate antibiotic treatment the
disease is self-limiting.
The incidence of CAP due to Enterobacteriaceae is
generally reported to be below 10%, though associated
mortality is high, and may reach 20% in confirmed cases and
22% in bacteraemia cases [50,51]. This high mortality rate is
likely to be due to the fact that infections with Gram-
negative bacteria (GNB) are often related to comorbid
illness and are more likely to occur in more vulnerable,
elderly patients [22,40]. Indeed, cardiac and cerebrovas-
cular disease, age >65 years and nursing home residency
have been shown to be independent risk factors for
Enterobacteriaceae [51]. It should also be noted that un-
common pathogens such as GNB and MRSA may not be
susceptible to first-line empirical antibiotic treatment [27],
highlighting a need for careful evaluation of risk factors for
multi-drug resistant (MDR) pathogens, particularly in
nursing home residents (see below).
Particular attention needs to be paid to patients who are
at risk of potentially being infected by Enterobacteriaceae
or other drug-resistant GNB since the prevalence of MDR
pathogens is increasing in Europe52 and in other areas in the
world.53 Enterobacteriaceae spp. are frequently isolated in
urinary tract infections, particularly in elderly people who
are residents of healthcare facilities, however, these
pathogens may cause pneumonia in such population and
first line antibiotic treatments will not be efficacious.27
Among these MDR Enterobacteriaceae species, the
increasing prevalence of ESBL-producing Klebsiella pneu-
moniae and carbapenemase-producing K. pneumoniae
(KPC-Kp) is particularly threatening. The mortality rate
associated with such cases is extremely high.54,55 Patients
must be screened in some countries including Greece, Italy,
The Middle East countries and in Asia Pacific. Surveillance
data in these regions on these particular resistant patho-
gens is urgently needed.
Viruses cannot be excluded when aetiology is examined.
Using novel PCR technology, viral disease (e.g. influenza,
parainfluenza, respiratory syncytial virus [RSV] and human
metapneumovirus) could be detected in a significant number
of patients [56]. Mortality due to viral pneumonia may be
similar to that associated with bacterial pneumonia [56,57].
Polymicrobial infections are often recognised in such cases
[58]. The interaction between viruses and bacteria is amatter
of debate. Viral infection may increase the pathogenicity of
bacteria mainly via stimulating the invasion process [59]. The
question whether antiviral therapy in addition to antibiotic
treatment is efficient has not yet been answered.Severity assessment
Assessment of severity is critical in the management of
patients with CAP, since it can affect both the selection of
the most appropriate therapy and outcome. The impor-
tance of this evaluation has meant that research into tools
for the assessment of severity in CAP patients has attractedconsiderable interest in recent years. Such tools can be
used to predict mortality and help decide the best setting
in which to provide patient care. A number of tools are
currently available, though the most widely used are the
CURB-65 index and Pneumonia Severity Index (PSI) score
[60e62]. The PSI score includes a total of 20 parameters (3
demographic, 5 comorbid conditions, 5 physical examina-
tion findings and 7 laboratory/imaging variables) assessed
at the time of clinical presentation and is designed to
determine the most appropriate treatment setting for each
patient [61]. Conversely the CURB-65 index comprises only
5 variables, with the modified Confusion, Respiratory rate,
low Blood pressure, age >65 years (CRB-65) index including
only 4, withdrawing the only laboratory criterion in CURB-
65 (blood urea) (Table 2) [60,61]. A number of studies
have reported that the CURB-65 index and the modified
CRB-65 are comparable to the PSI score with regard to
prediction of mortality from pneumonia (CAP) in both in-
patients and outpatients [12,60e65]. Consequently, the
CRB-65 may be preferred in general practice for assessment
of pneumonia severity due to its simplicity and lack of
laboratory parameters [20].
According to current guidelines, the decision to hospi-
talise should be validated against at least one objective
tool of mortality risk assessment (e.g. CURB-65, CRB-65 or
PSI score) (Table 3) [20,62]. In particular, hospitalisation is
generally warranted in patients with a CURB-65 score
greater than 2 or PSI scores of IV or above, though sub-
jective assessment of risk should also be carried out by a
physician [20,62]. Patients are defined as having severe CAP
if they require ICU admission, especially if they have septic
shock, or acute respiratory failure requiring intubation and
mechanical ventilation [20,62].
Biomarkers are an alternative means of assessing pneu-
monia severity or predicting mortality from CAP and a wide
range are under investigation, including C-reactive protein
(CRP) [66], procalcitonin (PCT) [15,16], blood urea nitrogen
[67], midregional proatrial natriuretic peptide (MR-proANP)
and midregional proadrenomedullin (MR-proADM) [68],
white blood cell count (WBC) [68] and copeptin [69]. Kru¨ger
and colleagues have compared the utility of a number of
these new biomarkers (MR-proANP, MR-proADM, copeptin,
WBC and PCT) with the CRB-65 index for the prediction of
short- and long-term mortality in patients with CAP [68].
While each of these biomarkers was found to be good
predictors of all-cause mortality from CAP and at least
comparable to the CRB-65 index, MR-proADM was the
strongest predictor. This suggests that the combination of
MR-proADM with CRB-65 may be better a predictor of
mortality from CAP than use of severity scores alone [68]. In
another study, PCT levels on admission were shown to
predict the severity and outcome of CAP with a similar
prognostic accuracy to the CRB-65 score [70]. Other bio-
markers which may have potential for prediction of mor-
tality in CAP include proadrenomedullin, cortisol and blood
glucose level [14,68,71,72].Age
CAP is predominantly a disease of the elderly, with inci-
dence rising steeply over the age of 70 years [12]. The
Table 3 Management strategies for patients with community-acquired pneumonia recommended by current guidelines [20,62].
ERS, 2011 IDSA/ATS, 2007
Diagnostic criteria  CAP should be suspected in patients presenting with a cough and at
least one of the following:
 New focal chest signs
 Fever lasting >4 days
 Dyspnoea/tachypnoea
 Diagnosis should be supported/confirmed by chest radiograph findings
 The amount of microbiological work-up should be determined by the
severity of pneumonia
 CAP should be suspected in patients presenting with evidence of
clinical signs and symptoms:
 Cough
 Fever
 Sputum production
 Pleuritic chest pain
 Demonstrable infiltrate by chest radiograph or other imaging with/
without supporting microbiological data
 Investigations for specific pathogens are advised only if it would
alter the standard (empirical) treatment decision (i.e. if a specific
pathogen is suspected)
Criteria for
hospitalisation
 The decision to hospitalise should be validated against an objective
tool of risk assessment (e.g. CRB-65)
 Hospitalisation should be seriously considered in patients with
CRB-65 scores 1
 Decision making about treatment settings should be supported by
clinical judgement and consideration given to non-clinical factors
 Severity of illness scores (e.g. CURB-65, PSI) should be used to
identify patients requiring hospital admission
 Hospitalisation is usually warranted in those with CURB-65 scores
2
 Objective criteria or scores should be supplemented with physician
determination of subjective factors (e.g. ability to take oral
medication)
Definition of
severe CAP
 Patients are defined as having severe CAP if they have at least two of
the following:
 Systolic blood pressure <90 mmHg
 Severe respiratory failure PaO2/FIO2 ratio <250
 Involvement of >2 lobes in chest radiograph (multilobar
involvement)
 Or one of the following:
 Requirement for mechanical ventilation
 Requirement for vasopressors >4 h (septic shock)
 Or three of the following IDSA/ATS minor criteria:
 Respiratory rate 30 breaths/min
 PaO2/FiO2 ratio 250
 Multilobar infiltrates
 Confusion/disorientation
 Uraemia (BUN level 20 mg/dL)
 Leukopenia (white cell count <4000 cells/mm3)
 Thrombocytopenia (platelet count <100,000 cells/mm3)
 Hypothermia (core temperature <36 C)
 Hypotension requiring aggressive fluid resuscitation
 Severe CAP is defined by the requirement for ICU admission plus
either of the following major criteria or any three of the minor
criteria:
 Major criteria
- Invasive mechanical ventilation
- Septic shock with need for vasopressors
 Minor criteria:
- Respiratory rate 30 breaths/min
- PaO2/FiO2 ratio 250
- Multilobar infiltrates
- Confusion/disorientation
- Uraemia (BUN level 20 mg/dL)
- Leukopenia (white cell count <4000 cells/mm3)
- Thrombocytopenia (platelet count <100,000 cells/mm3)
- Hypothermia (core temperature <36 C)
- Hypotension requiring aggressive fluid resuscitation
Recommended
antibiotic therapy
 Initial antibiotic therapy should be empirical and initiated as soon
as possible
 Options for non-ICU hospitalised patients include:
 Outpatient treatment:
 Previously healthy with no risk factors for DRSP infection: mac-
rolide or doxycycline
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162 T. Welteimpact of CAP is also greater in older individuals since they
are more likely to be hospitalised than younger patients and
have a higher risk of mortality, with the mortality rate
increasing with every decade until the eighth decade
(Fig. 1) [12,22]. Mortality from CAP has been shown to be
independently associated with age, even when comorbidity
and severity of illness are taken into account [22]. Indeed,
CAP appears to be a clinically distinct entity in older pa-
tients above the age of 65 years, being associated with
more severe disease and presenting with fewer classical
symptoms (e.g. fever and chest pain) than in younger in-
dividuals. Mortality from CAP is also higher in older pa-
tients, particularly in those with comorbidity [73]. The
importance of age in patients with CAP is well recognised in
current severity assessment tools, being a highly influential
factor in both the PSI score and CURB-65 index [60,61].
Mortality prediction in elderly patients is still based on the
same severity scoring systems (e.g. PSI classes, CRB-65 or
CURB-65 scoring) as they are equally useful in older and
younger patients [64]; however, such scoring systems may
be reliable to predict mortality and poor outcome if a pa-
tient has healthcare-associated pneumonia (HCAP) [65].
The rationale for the much higher incidence and mor-
tality from CAP in older individuals is not entirely clear, but
is likely to be related to the high degree of comorbidity
present in this population. However, changes to the im-
mune system and lung physiology as a result of ageing are
also likely to play a role [30,74].Presence of comorbidity
Comorbid illnesses are significantly more common in elderly
patients with CAP and have a marked impact on outcome,
with congestive heart failure, cerebrovascular disease and
chronic liver disease all found to be independent risk fac-
tors for increased 30 day mortality [22,73]. In patients with
defined comorbidities, mortality has been found to be
highest in patients with malignant disease, though pulmo-
nary comorbidity [excluding COPD] and dementia are also
associated with high mortality (Table 4) [12].
Risk factors for developing CAP in older individuals
include COPD, immunosuppression, smoking, congestive
heart failure, diabetes, malignancy and previous hospital-
isation for CAP [10]. Acute myocardial infarction [AMI] is
common among hospitalised patients with CAP, being pre-
sent in 15% of those with severe CAP, with risk of AMI
increasing with higher PSI scores [75]. Furthermore, AMI is
strongly associated with clinical failure and is reported to
be the second-most common aetiology (after severe sepsis)
associated with respiratory deterioration. This indicates
that investigations to rule out AMI should form part of the
initial work-up of hospitalised patients with CAP experi-
encing clinical failure [75]. Further incident cardiac com-
plications, including new or worsening heart failure and
new or worsening arrhythmias, are also frequent in patients
with CAP and are associated with increased short-term
mortality. Risk factors for such complications include
older age, nursing home residence, pre-existing cardiovas-
cular disease and severe pneumonia [76].
Immunocompromised patients, such as those with
human immunodeficiency virus (HIV) infection [77],
Figure 1 Distribution of in-hospital deaths of patients hos-
pitalised with community-acquired pneumonia according to
age. Data comprise patients included in the database of the
Nationwide German programme for quality in healthcare be-
tween 2005 and 2006 (n Z 388,406).
Reproduced with permission from Ewig et al. Thorax 2009 [12].
Managing high-risk CAP patients 163pregnancy [78], malignancy [79], or transplant immuno-
suppression [80], carry a high risk of developing CAP and
altered immune function also confers a higher mortality
rate than that observed in immunocompetent patients
[81,82]. Furthermore, immunosuppressed patients with
CAP are more likely to experience complications such as
respiratory failure, acute respiratory distress syndrome or
pleural effusion, and have increased susceptibility to
atypical pathogens [81,83,84].Impact of setting
Residence status has a marked impact on CAP outcome,
with mortality rates being around 4-fold higher among
elderly nursing home residents compared with those living
in the community [22,27,85]. Nursing home-acquired
pneumonia (NHAP) is the largest subgroup of healthcare-
associated pneumonia (HCAP) and the proportion of in-
dividuals in this category is likely to increase dramatically
in the coming years due to the expected increase in the
number of adults residing in nursing homes [27]. The high
mortality rate associated with nursing home residency is
likely to be explained by the fact that such patients are
older, have greater comorbidity and more severe functional
impairment than CAP patients [12]. Differences in the
mortality rates of HCAP and CAP may also be due to dif-
ferences in aetiology. While some studies have reported
similar aetiological agents in HCAP and CAP, with S. pneu-
moniae being the most frequently isolated pathogen in
each setting [85,86], others have reported increased in-
cidences of GNB, MRSA and MDR microorganisms in patients
with HCAP [27,33,87e90]. Although the susceptibility of the
Enterobacteriaceae species isolated in these studies was
not assessed, presence of these pathogens, along with
MRSA or MDR microorganisms is associated with a higher
mortality risk in HCAP [12,22].
Although the concept of HCAP was introduced to take
account of the increasing numbers of elderly patients livingin nursing homes, definitions for HCAP are heterogeneous
and the optimal management is unclear, potentially leading
to overtreatment of the condition [91]. Consequently,
subdivision of CAP according to key risk factors such as age
and functional status may assist in the selection of the most
appropriate treatment [91]. Approaches to categorising
patients with CAP should also consider their risk of devel-
oping MDR pathogens and take residence and previous
antimicrobial treatment into account in the selection of
appropriate antimicrobial coverage [92,93].Managing the at risk patient
CAP associated mortality is highest within the first 5 days of
hospitalisation, with risk being highest during the first day
after admission, across all CRB-65 classes. Furthermore,
failure of initial empiric treatment is an independent risk
factor for death from CAP [21,22], highlighting the impor-
tance of early treatment with the most effective therapy,
even for patients at low risk of poor outcomes [12]. A number
of factors should be taken into account in the consideration
of empirical therapeutic management of patients with CAP,
including age, severity of disease, residency, comorbidity
and functional status, as well as local resistance patterns. In
particular, the increasing prevalence of b-lactam resistance
among pneumococci has complicated the treatment of CAP
and other respiratory tract infection, with most resistant
isolates being resistant to multiple antimicrobial classes
[94,95]. The high prevalence of resistance to macrolides in
many countries also limits the efficacy of this drug class in the
treatment of pneumococcal infections [96]. In contrast, the
prevalence of fluoroquinolone resistance among S. pneu-
moniae isolates remains low, with the most active agents
being moxifloxacin, gatifloxacin and gemifloxacin [97e100].
Of note, gatifloxacin for systemic use is withdrawn from the
market due to toxicity [101].
As the aetiology of CAP is often unknown [25], recom-
mended antibiotic treatment for CAP is usually empirical,
with appropriate agents being selected according to dis-
ease severity and initiated as soon as possible (Table 3)
[20,62,102]. Although coverage of atypical pathogens is not
currently recommended for non-severe CAP patients
[20,62], broader antibiotic therapy compensates for un-
usual circumstances, particularly for patients with
increased risk factors. Indeed use of antimicrobial regimens
with atypical coverage has been shown to be associated
with better outcomes, suggesting that consideration should
be given to empiric use of such regimens for all hospitalised
patients [103]. The increasing incidence of GNB, MRSA and
MDR pathogens among individuals with higher severity
scores supports this view, since such infections may not be
susceptible to regular first-line CAP treatment
[27,33,87e90]. Furthermore, it suggests a need for careful
evaluation of risk factors for MDR pathogens (e.g. previous
antibiotic treatment, recent hospitalisation, chronic respi-
ratory disease and functional status) for all CAP patients,
particularly those presenting from nursing homes [27].
For outpatients with no modifying risk factors (e.g. drug-
resistant S. pneumoniae infection, Gram-negative or Pseu-
domonas aeruginosa infection), guidelines recommend
standard therapy with a macrolide or a tetracycline (Table
Table 4 Patient mortality from community-acquired
pneumonia according to comorbidity.
Comorbidity 2005
deaths (%)
2006
deaths (%)
Total (%)
Malignancy (other
than bronchial)
27.65 28.66 28.2
Lung cancer 25.07 25.33 25.21
Pulmonary diseases
(other than COPD)
24.03 24.82 24.45
Dementia 21.93 22.76 22.36
Renal diseases 20.2 21.3 20.79
CNS disorders 19.27 19.54 19.41
Cardiac comorbidity 17.06 17.63 17.35
Diabetes mellitus 13.41 13.88 13.66
Liver diseases 12.26 13.6 12.93
COPD 9.85 10.37 10.12
Total 17.08 17.75 17.43
No comorbidity 12.5 13.35 12.95
COPD, chronic obstructive pulmonary disease.
Reproduced with permission from Ewig et al. Thorax 2009 [12].
164 T. Welte3) [20,62]. Evidence suggests that macrolide/b-lactam
combination therapy is more effective than b-lactam
monotherapy in hospitalised patients and is associated with
lower risk of treatment failure [104]. For this reason,
guidelines recommend combination therapy (e.g. macro-
lide/b-lactam) as an option for initial empirical treatment
for hospitalised patients with CAP [20,62].
Data indicate that fluoroquinolones (moxifloxacin,
gemifloxacin and levofloxacin) are also effective as mono-
therapy for hospitalised CAP patients [105,106], though
ciprofloxacin is contraindicated due to its absence of
pneumococcal coverage. Studies investigating the efficacy
of fluoroquinolones (moxifloxacin, and levofloxacin) in the
treatment of CAP have generally reported faster resolution
of symptoms when compared with b-lactam monotherapy
or macrolide/b-lactam combination therapy with compa-
rable adverse events [107e111]. Levofloxacin (500 mg) has
been shown to be at least as effective as amoxicillin/
clavulanate plus clarithromycin in hospitalised CAP patients
[110], and cefotaxime plus ofloxacin in CAP patients
requiring intensive care admission [111]. Similarly, moxi-
floxacin was as effective as amoxicillin, with or without
clarithromycin, in patients with CAP [95] and was also as
effective as amoxicillin-clavulanate plus roxithromycin in
CAP patients with risk factors (i.e. older age, alcoholism
and comorbidities, including COPD and diabetes mellitus)
[112]. Moxifloxacin monotherapy was also shown to be non-
inferior to levofloxacin plus ceftriaxone in patients hospi-
talised with CAP in the MOTIV (MOxifloxacin Treatment IV)
study, with clinical cure rates being comparable across PSI
severity risk classes, including those with PSI IV and V [113].
Meta-analysis of trials comparing treatment with fluo-
roquinolones and macrolides in patients with mild-to-
moderate CAP shows an advantage for fluoroquinolones
with regard to treatment failure (relative risk [RR] 0.78)
and microbiological failure (RR 0.63), with adverse events
requiring discontinuation also being more frequent with
macrolides [114].For severe CAP cases requiring ICU admission, combi-
nation therapy involving a b-lactam plus a macrolide or a
fluoroquinolone is recommended to extend the antimicro-
bial coverage and improve survival [20,62]. Use of macro-
lides was associated with decreased mortality in patients
with severe sepsis due to pneumonia [28]. However, fluo-
roquinolones may be used as monotherapy in patients with
severe pneumonia without septic shock [20]. The beneficial
effect of macrolides in severe CAP may be due to the
immunomodulatory properties of these agents [115]. This is
supported by mouse models that suggest that use of mac-
rolides to attenuate the inflammatory response in second-
ary pneumonia following influenza is associated with better
outcomes [116]. Nevertheless, additional data are required
in order to clarify the mechanism underlying the benefit of
macrolides in this setting.
Selection of appropriate empirical antimicrobial therapy
for the treatment of CAP should also take into account the
need for rapid bactericidal action and penetration into the
site of infection. Ceftaroline has been shown to provide
potent antimicrobial activity against common CAP patho-
gens, displaying lower minimum inhibitory concentrations
for S. pneumoniae and S. aureus in vitro when compared
with ceftriaxone and other cephalosporins [117]. With re-
gard to macrolide antibiotics, the pharmacodynamics of
azithromycin provides a number of advantages over eryth-
romycin and newer macrolides, including its long half-life
and good tissue penetration, allowing for once-daily
dosing and shorter courses of therapy [118]. The fluo-
roquinolones moxifloxacin, levofloxacin and sparfloxacin
are bactericidal against S. pneumoniae, with moxifloxacin
providing the fastest kill rate along with effective pene-
tration in respiratory tissues [119,120].
Patient factors are important parameters to be taken
into consideration in the selection of empirical antibiotics
for the treatment of CAP, since they can have a marked
impact on outcome. CAP is primarily a disease of elderly
patients, with incidence rising steeply over the age of 70
years. This vulnerable population requires prompt, effec-
tive treatment to avoid respiratory deterioration, yet few
studies have evaluated antibiotics in the treatment of CAP
in the elderly. Nevertheless, the efficacy of sequential IV/
oral moxifloxacin in the treatment of CAP has been
compared with IV/oral levofloxacin in hospitalised elderly
(65 years) patients [121]. Overall cure rates at the test-of-
cure visit (5e12 days post therapy) in this study were
similar between groups (moxifloxacin 92.9%, levofloxacin
87.9%), with comparable cure rates also being demon-
strated for patients 75 years old (94.5% vs 90%, respec-
tively). Moxifloxacin was also associated with faster clinical
recovery than levofloxacin therapy (97.9% at 3e5 days after
the start of therapy vs 90% for levofloxacin; PZ 0.01), with
a comparable safety profile.
A further aspect to be considered is that elderly patients
frequently have comorbid conditions, particularly cardiac
conditions, requiring a need for multiple medications [122];
it thus is important to review the cardiac risk of the agents
themselves. Review of the short-term cardiac effects of
selected antibiotics (azithromycin, amoxicillin, ciprofloxa-
cin and levofloxacin) revealed a small absolute increase in
cardiovascular deaths for patients receiving azithromycin,
which was most pronounced among patients at higher risk
Managing high-risk CAP patients 165of cardiovascular disease [123]. Furthermore, risk of car-
diovascular death was found to be significantly greater with
azithromycin than with either amoxicillin or ciprofloxacin,
though the risk did not differ significantly from that with
levofloxacin. In addition, risk of QTc prolongation has been
associated with both macrolides and fluoroquinolones, with
cardiac arrhythmias being reported with the fluo-
roquinolones sparfloxacin and grepafloxacin [124e127].
However, moxifloxacin and levofloxacin were found to have
comparable cardiac rhythm safety profiles in hospitalised
elderly CAP patients [122]. Furthermore, the frequency of
new arrhythmias in this high-risk elderly population treated
with these two fluoroquinolones did not exceed that ex-
pected in healthy elderly subjects, or those with cardiac
disease. The safety profile of moxifloxacin has also been
shown to be comparable to that of comparator antibiotics
(b-lactams  macrolides, macrolides and fluoroquinolones)
in a recent review of clinical studies across all indications,
with no increase in cardiac events being reported. [128]
Conclusions
Therapeutic management of patients with bacterial CAP
involves the need to cover a broad spectrum of pathogens
including S. pneumoniae, atypicals and Enter-
obacteriaceae. Coverage of atypical pathogens appears to
be particularly important, since use of antimicrobials with
activity against such pathogens has been shown to be
associated with better outcomes. As mortality from CAP
usually occurs within the first five days, antibiotic agents
must also be rapidly bactericidal with a fast clinical efficacy
and show excellent penetration into the bronchopulmonary
compartment. Moreover, agents need to demonstrate a
good safety profile, as patients often are elderly with a
variety of comorbidities (most likely cardiovascular) and
receiving multiple co-medications. A range of antibiotic
agents are available for the treatment of outpatients and
inpatients with CAP. While macrolides and b-lactam anti-
biotics are effective in the treatment of CAP, the increasing
prevalence of resistance to these agents raises concerns
about their continued effectiveness. Fluoroquinolones
display excellent activity against common and atypical
respiratory pathogens responsible, with data particularly
supporting their use in high-risk patients. Of these agents,
moxifloxacin appears to be the most potent, demonstrating
equivalent efficacy to a variety of combination treatments
when used as monotherapy, with good tolerability in a
range of patients, including the elderly and those with co-
morbid conditions. It should be noted, however, that se-
lection of an appropriate antibiotic must take into account
the associated risks, since there are warnings and pre-
cautions on the labels of all agents (macrolides, b-lactams
and fluoroquinolones). Therefore, careful assessment of
the benefit/risk ratio should be made on an individual basis
before prescription of any antibiotic agent, particularly for
vulnerable patients.
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